Big pharma: Eli Lilly stock erases 6 years of dividends after failed drug trial

(NaturalNews) What investors had hoped would build into yet another 2.68 percent dividend yield for pharmaceutical behemoth Eli Lilly has turned into a massive financial letdown after trials of solanezumab, a supposedly promising experimental drug for Alzheimer’s disease and other forms of dementia, showed less than favorable efficacy in the latest clinical trials. Reports indicate…

View original article

Powered by WPeMatico